Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06275620 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN)

StatusEnrolling by Invitation
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated October 30, 2024 (before its estimated November 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoints: 1 to 2v3 Show 6 more changesShow less
    • Enrollment target: 18 to 24
    • Primary completion date: Jul 2025 to Nov 2025
    • Study completion date: Aug 2029 to Dec 2029
    • Secondary endpoints: 5 to 12
    • Study description expanded, about 66 words
    • Eligibility criteria shortened, about 2 words
  2. Study title shortened, about 17 wordsv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This Phase 2 study is a non-randomized, open-label, study of the safety of AGTC-501 in participants with XLRP who have previously been treated with a full-length AAV vector-based gene therapy targeting RPGR protein.
Trial Details
NCT Number NCT06275620
Lead Sponsor Beacon Therapeutics
Conditions
(from sponsor)		 X-Linked Retinitis Pigmentosa
Related terms Retinal Degeneration
Enrollment 24 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov